Antihypertensive and Water and Sodium Balance Effects of Felodipine, A New Vasodilating Calcium Antagonist, in Hypertensive Patients

G. Leonetti, M. Fruscio, L. Terzoli, L. Rupoli, R. Gradnik, L. Sampieri, C. Cuspidi, L. Boselli, G. Bolla, A. Zanchetti

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Felodipine, a new dihydropyridine derivative with a selective action on vascular smooth muscle, was investigated in 2 short term studies in hypertensive patients. In the first study, oral administration of felodipine 12.5mg three times daily in a preliminary tablet formulation for 3 days significantly reduced supine and upright blood pressure with only a slight increase in heart rate and no clinically relevant signs of sodium and water retention. By increasing each dose to 25 and 50mg three times daily, there was a further, but quite moderate, decrease in blood pressure; however, this was accompanied by an increase in heart rate and a tendency towards a reduction of creatinine clearance and urinary sodium output. In the second study, a new oral formulation containing 10mg felodipine, administered twice daily for 7 days, was effective in lowering blood pressure without a clinically relevant tachycardia. Following the first dose of felodipine, urinary sodium excretion was slightly increased while potassium excretion showed only minor changes. The new calcium antagonist, felodipine, lowers blood pressure without the clinically relevant adverse reactions commonly related to other direct vasodilator antihypertensive drugs.

Original languageEnglish
Pages (from-to)185-191
Number of pages7
JournalDrugs
Volume29
Issue number2
DOIs
Publication statusPublished - 1985

Fingerprint

Felodipine
Antihypertensive Agents
Blood pressure
Sodium
Calcium
Water
Blood Pressure
Heart Rate
Vasodilator Agents
Vascular Smooth Muscle
Tachycardia
Tablets
Oral Administration
Muscle
Creatinine
Potassium
Derivatives

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Leonetti, G., Fruscio, M., Terzoli, L., Rupoli, L., Gradnik, R., Sampieri, L., ... Zanchetti, A. (1985). Antihypertensive and Water and Sodium Balance Effects of Felodipine, A New Vasodilating Calcium Antagonist, in Hypertensive Patients. Drugs, 29(2), 185-191. https://doi.org/10.2165/00003495-198500292-00033

Antihypertensive and Water and Sodium Balance Effects of Felodipine, A New Vasodilating Calcium Antagonist, in Hypertensive Patients. / Leonetti, G.; Fruscio, M.; Terzoli, L.; Rupoli, L.; Gradnik, R.; Sampieri, L.; Cuspidi, C.; Boselli, L.; Bolla, G.; Zanchetti, A.

In: Drugs, Vol. 29, No. 2, 1985, p. 185-191.

Research output: Contribution to journalArticle

Leonetti, G, Fruscio, M, Terzoli, L, Rupoli, L, Gradnik, R, Sampieri, L, Cuspidi, C, Boselli, L, Bolla, G & Zanchetti, A 1985, 'Antihypertensive and Water and Sodium Balance Effects of Felodipine, A New Vasodilating Calcium Antagonist, in Hypertensive Patients', Drugs, vol. 29, no. 2, pp. 185-191. https://doi.org/10.2165/00003495-198500292-00033
Leonetti, G. ; Fruscio, M. ; Terzoli, L. ; Rupoli, L. ; Gradnik, R. ; Sampieri, L. ; Cuspidi, C. ; Boselli, L. ; Bolla, G. ; Zanchetti, A. / Antihypertensive and Water and Sodium Balance Effects of Felodipine, A New Vasodilating Calcium Antagonist, in Hypertensive Patients. In: Drugs. 1985 ; Vol. 29, No. 2. pp. 185-191.
@article{d76609e0a17a479ea7de79a3263442b9,
title = "Antihypertensive and Water and Sodium Balance Effects of Felodipine, A New Vasodilating Calcium Antagonist, in Hypertensive Patients",
abstract = "Felodipine, a new dihydropyridine derivative with a selective action on vascular smooth muscle, was investigated in 2 short term studies in hypertensive patients. In the first study, oral administration of felodipine 12.5mg three times daily in a preliminary tablet formulation for 3 days significantly reduced supine and upright blood pressure with only a slight increase in heart rate and no clinically relevant signs of sodium and water retention. By increasing each dose to 25 and 50mg three times daily, there was a further, but quite moderate, decrease in blood pressure; however, this was accompanied by an increase in heart rate and a tendency towards a reduction of creatinine clearance and urinary sodium output. In the second study, a new oral formulation containing 10mg felodipine, administered twice daily for 7 days, was effective in lowering blood pressure without a clinically relevant tachycardia. Following the first dose of felodipine, urinary sodium excretion was slightly increased while potassium excretion showed only minor changes. The new calcium antagonist, felodipine, lowers blood pressure without the clinically relevant adverse reactions commonly related to other direct vasodilator antihypertensive drugs.",
author = "G. Leonetti and M. Fruscio and L. Terzoli and L. Rupoli and R. Gradnik and L. Sampieri and C. Cuspidi and L. Boselli and G. Bolla and A. Zanchetti",
year = "1985",
doi = "10.2165/00003495-198500292-00033",
language = "English",
volume = "29",
pages = "185--191",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Antihypertensive and Water and Sodium Balance Effects of Felodipine, A New Vasodilating Calcium Antagonist, in Hypertensive Patients

AU - Leonetti, G.

AU - Fruscio, M.

AU - Terzoli, L.

AU - Rupoli, L.

AU - Gradnik, R.

AU - Sampieri, L.

AU - Cuspidi, C.

AU - Boselli, L.

AU - Bolla, G.

AU - Zanchetti, A.

PY - 1985

Y1 - 1985

N2 - Felodipine, a new dihydropyridine derivative with a selective action on vascular smooth muscle, was investigated in 2 short term studies in hypertensive patients. In the first study, oral administration of felodipine 12.5mg three times daily in a preliminary tablet formulation for 3 days significantly reduced supine and upright blood pressure with only a slight increase in heart rate and no clinically relevant signs of sodium and water retention. By increasing each dose to 25 and 50mg three times daily, there was a further, but quite moderate, decrease in blood pressure; however, this was accompanied by an increase in heart rate and a tendency towards a reduction of creatinine clearance and urinary sodium output. In the second study, a new oral formulation containing 10mg felodipine, administered twice daily for 7 days, was effective in lowering blood pressure without a clinically relevant tachycardia. Following the first dose of felodipine, urinary sodium excretion was slightly increased while potassium excretion showed only minor changes. The new calcium antagonist, felodipine, lowers blood pressure without the clinically relevant adverse reactions commonly related to other direct vasodilator antihypertensive drugs.

AB - Felodipine, a new dihydropyridine derivative with a selective action on vascular smooth muscle, was investigated in 2 short term studies in hypertensive patients. In the first study, oral administration of felodipine 12.5mg three times daily in a preliminary tablet formulation for 3 days significantly reduced supine and upright blood pressure with only a slight increase in heart rate and no clinically relevant signs of sodium and water retention. By increasing each dose to 25 and 50mg three times daily, there was a further, but quite moderate, decrease in blood pressure; however, this was accompanied by an increase in heart rate and a tendency towards a reduction of creatinine clearance and urinary sodium output. In the second study, a new oral formulation containing 10mg felodipine, administered twice daily for 7 days, was effective in lowering blood pressure without a clinically relevant tachycardia. Following the first dose of felodipine, urinary sodium excretion was slightly increased while potassium excretion showed only minor changes. The new calcium antagonist, felodipine, lowers blood pressure without the clinically relevant adverse reactions commonly related to other direct vasodilator antihypertensive drugs.

UR - http://www.scopus.com/inward/record.url?scp=0021923386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021923386&partnerID=8YFLogxK

U2 - 10.2165/00003495-198500292-00033

DO - 10.2165/00003495-198500292-00033

M3 - Article

VL - 29

SP - 185

EP - 191

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 2

ER -